Unlock instant, AI-driven research and patent intelligence for your innovation.

Cardio- and renosafe antidiabetic therapy

A technology for diabetes and type 2 diabetes, which can be applied to metabolic diseases, medical preparations containing active ingredients, organic active ingredients, etc., and can solve problems such as lack of safety information

Pending Publication Date: 2021-03-02
BOEHRINGER INGELHEIM INT GMBH
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients with advanced CKD have been largely excluded from previous studies of CV outcomes of glucose-lowering agents, resulting in a lack of safety information available for this particular population

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cardio- and renosafe antidiabetic therapy
  • Cardio- and renosafe antidiabetic therapy
  • Cardio- and renosafe antidiabetic therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0299]In one embodiment, diabetic patients as referred to herein may include patients who have not been previously treated with antidiabetic drugs (drug naïve patients). Thus, in one embodiment, the treatments described herein may be used in untreated patients. In certain embodiments of the treatment of the invention, the DPP-4 inhibitor, preferably linagliptin, may be used in such patients alone or in combination with one or more other antidiabetic agents. In another embodiment, diabetic patients within the meaning of the present invention may include patients pretreated with conventional antidiabetic background medications, such as for example patients with advanced or late stage type 2 diabetes (including conventional antidiabetic therapy failed patients), such as, for example, patients with insufficient glycemic control with one, two or more conventional oral and / or parenteral antidiabetic drugs as defined herein, such as, for example, despite treatment with metformin, thi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to cardio- and renosafe antidiabetic therapy.

Description

technical field [0001] The present invention relates to certain DPP-4 inhibitors, preferably linagliptin, optionally in combination with one or more other active agents, for cardiovascular and / or renal safety in patients with diabetes, preferably type 2 diabetes antidiabetic treatment (especially long-term) and / or for providing certain micro and / or macrovascular benefits in these patients, including (humans) with or at risk of (micro and / or macro) vascular disease In patients such as for example patients suffering from or at risk of cardiovascular and / or microvascular (e.g. renal / kidney) disease, such as for example at high or increased vascular (cardio-renal) risk, such as for example at Patients at high or increased risk of cardiovascular and / or renal events or complications. [0002] In one embodiment, patients at high vascular risk (especially type 2 diabetic patients) include patients at high cardiovascular risk, most of whom also have kidney disease (CKD, an important r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/522A61P3/10
CPCA61K31/522A61P3/10A61K45/06A61K2300/00A61K9/0053
Inventor M·冯埃纳滕O-E·乔汉森
Owner BOEHRINGER INGELHEIM INT GMBH